These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 658069)

  • 1. Progestogens in prostatic cancer.
    Denis L; Declercq G
    Eur Urol; 1978; 4(3):162-6. PubMed ID: 658069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
    Fosså SD; Jahnsen JU; Karlsen S; Ogreid P; Haveland H; Trovåg A
    Eur Urol; 1985; 11(1):11-6. PubMed ID: 3157571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J; Spona J
    Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients.
    Flamm J; Spona J
    Int Urol Nephrol; 1988; 20(2):131-7. PubMed ID: 2968326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer.
    Fowler JE; Whitmore WF
    Cancer; 1982 Apr; 49(7):1373-7. PubMed ID: 7059952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
    Damber JE; Bergh A; Landström M; Tomić R
    J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of advanced prostatic carcinoma with medroxyprogesterone.
    Rafla S; Johnson R
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):261-7. PubMed ID: 4208339
    [No Abstract]   [Full Text] [Related]  

  • 12. Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report.
    Varenhorst E; Björnlert U; Carlström K
    Scand J Urol Nephrol; 1981; 15(2):157-9. PubMed ID: 7330610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of cyproterone acetate in patients with prostatic cancer.
    Isurugi K; Fukutani K; Ishida H; Hosoi Y
    J Urol; 1980 Feb; 123(2):180-3. PubMed ID: 7354512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cyproterone acetate on advanced carcinoma of the prostate.
    Geller J; Vazakas G; Fruchtman B; Newman H; Nakao K; Loh A
    Surg Gynecol Obstet; 1968 Oct; 127(4):748-58. PubMed ID: 5675191
    [No Abstract]   [Full Text] [Related]  

  • 16. A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma.
    Sinha AA; Blackard CE; Seal US
    Cancer; 1977 Dec; 40(6):2836-50. PubMed ID: 201356
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of treatment with oral 6-methyl-17-hydroxyprogesterone acetate in endometrial adenocarcinoma. Histochemical and ultrastructural aspects].
    Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S; Patton R
    Minerva Ginecol; 1981 Apr; 33(4):293-306. PubMed ID: 7243070
    [No Abstract]   [Full Text] [Related]  

  • 19. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
    Németh A; Morvay J; Vécsei B
    Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.